GSK asthma drug Nucala’s Cosmos study demonstrates safety profile
Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period. The company enrolled a total of 651 patients in
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.
Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive
Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve